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Background: Data are limited regarding the presence, distribution and extent of 
subclinical atherosclerosis in middle-aged populations. 
Methods and Results: The PESA (Progression of Early Subclinical Atherosclerosis) 
study prospectively enrolled 4184 asymptomatic participants aged 40-54 years (mean 
age 45.8 years, 63.3% male) to evaluate the systemic extent of atherosclerosis in the 
carotid, abdominal aortic and ilio-femoral territories by 2D/3D ultrasound and coronary 
artery calcification (CAC) by computed tomography. The extent of subclinical 
atherosclerosis, defined as presence of plaque or CAC≥1, was classified as focal (one 
site affected), intermediate (2-3 sites) or generalized atherosclerosis (4-6 sites) after 
exploring each vascular site (right/left carotids, aorta, right/left ilio-femorals and 
coronary arteries). 
Subclinical atherosclerosis was present in 62.5% of participants (70.7% of men; 48.4% 
of women). Intermediate and generalized atherosclerosis was identified in 41.2%. 
Plaques were most common in the ilio-femorals (43.7%), followed by carotids (31.3%) 
and aorta (24.5%), while CAC was present in 17.7%. Among participants with low 
Framingham Heart Study (FHS) 10-year risk, subclinical disease was detected in 
58.2%, with intermediate or generalized disease in 35.7%. When assessing longer-term 
risk (30-year Framingham Heart Study), 82.5% of participants at high-risk had 
atherosclerosis, with 65.8% classified as intermediate or generalized.  
Conclusions: Subclinical atherosclerosis was highly prevalent in this middle-aged 
population, with almost 50% of participants classified as having intermediate or 
generalized disease. Most participants at high FHS risk had subclinical disease; 
nonetheless, extensive atherosclerosis was also present in a substantial number of low-
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The natural history of atherosclerosis involves a protracted subclinical phase, with 
disease often detected only at an advanced symptomatic stage or following a 
cardiovascular (CV) event. This is of particular importance as CV events are often fatal, 
and many deaths attributable to coronary artery disease are sudden1. There is thus a 
clear need to identify disease at an early stage, and as a result primary prevention forms 
the cornerstone of management. Currently, risk stratification scores for prevention rely 
on the presence of identifiable risk factors and levels of biochemical markers. However, 
conventional risk assessment has well-recognized limitations, notably in lower-risk 
groups such as women and younger people2, 3. Detection of atherosclerosis in its 
subclinical stage may help identify strategies to arrest disease development. The clinical 
significance of early detection was recently highlighted in the US High Risk Plaque 
Study, which has demonstrated an association between the presence of subclinical 
disease and CV events4. 
 
The introduction of noninvasive imaging techniques has unlocked the potential to 
evaluate atherosclerosis in asymptomatic populations. Specific imaging modalities 
include vascular ultrasound, computed tomography (CT), and magnetic resonance 
imaging5, 6. Many imaging studies evaluated individual vascular territories, but given 
the systemic nature of atherosclerosis a multi-territory analysis has the potential to 
provide a more comprehensive overview of the distribution and burden of 
atherosclerosis.  
 
The PESA (Progression of Early Subclinical Atherosclerosis) study evaluates 
atherosclerosis in the carotid, aortic, coronary and ilio-femoral territories using 





population7. Through the evaluation of multiple vascular beds in relatively young 
individuals we aim to improve understanding of the origin and progression of 
atherosclerosis. Here, we present the prevalence, vascular distribution and extent of 




The rationale and design of the PESA study has been previously described7. In brief, 
PESA-CNIC Santander is a prospective cohort study of asymptomatic employees of the 
Santander Bank in Madrid, aged 40 to 54 years and consecutively recruited between 
June 2010 and February 2014. Participants with prior CV disease and any condition 
reducing life expectancy or affecting study adherence were not included. Participants 
were examined at baseline by ankle-brachial index (ABI), vascular ultrasound and non-
contrast CT, and will be followed up at 3- and 6-years. In addition, each visit includes 
clinical interviews, physical examination, fasting blood draw, urine sample, and a 12-
lead electrocardiogram. The study protocol has been approved by the Instituto de Salud 
Carlos III Ethics Committee and all eligible participants have provided written 
informed consent. 
 
CV risk factors were determined from blood samples and interviews, as follows: 1) 
diabetes: fasting plasma glucose ≥126 mg/dL, or treatment with insulin or oral 
hypoglycemic medication8; 2) arterial hypertension: systolic blood pressure ≥140 
mmHg, diastolic blood pressure ≥90 mmHg, or use of antihypertensive medication8; 3) 
dyslipidemia: total cholesterol ≥240 mg/dL, LDL-cholesterol ≥160 mg/dL, HDL-





status, or a lifetime consumption of >100 cigarettes5, 10; 5) family history of CV disease: 
first degree-relative diagnosed with atherosclerosis before the age of 55 years in men 
and 65 in women11. CV risk was assessed by the 10-year risk of coronary heart disease 
and the 30-year risk of CV disease from the Framingham Heart Study (FHS)10, 12, and 
additionally by the European Society of Cardiology’s SCORE (Systematic COronary 
Risk Evaluation), which calculates 10-year risk of fatal CV disease11. Low, moderate 
and high-risk cut-off values were <10%, ≥10 to 20% and >20% for the FHS and <1%, 
≥1 to <5%, ≥5 for the European SCORE. 
 
Vascular ultrasound imaging  
The 2D/3D vascular ultrasound protocol has been described13. Presence of 
atherosclerotic plaques was assessed by cross-sectional sweep of carotids, infra-renal 
abdominal aorta and ilio-femoral arteries. Plaque was defined as a focal protrusion into 
the arterial lumen of thickness >0.5 mm or >50% of the surrounding intima-media 
thickness (IMT), or a diffuse thickness >1.5 mm measured between the media-
adventitia and intima-lumen interfaces13, 14. Semi-automated detection of IMT was also 
assessed at the level of the posterior wall of the common carotid and femoral arteries in 
longitudinal views. Values >0.9 were considered abnormal, as established in previous 
studies14 and guidelines15. Ultrasound studies were analyzed with QLab9 (Philips 
Healthcare, Bothel, Seattle) at the CNIC Core Imaging Laboratory, as reported13. Good 
reproducibility was found for presence of plaque in all territories (kappa = 0.75 for 
carotids, 0.89 for aorta, 0.88 for ilio-femorals). Similarly, excellent intraclass 
correlation coefficient (ICC>95%) was found for both carotid and femoral IMT 
measurements. Imaging quality was evaluated as optimal, suboptimal or non-





calculated as the ratio of the systolic blood pressure in the posterior tibial artery to the 
systolic blood pressure in the brachial artery using Doppler ultrasound and a standard 
sphygmomanometer. Values of ABI<0.916 were considered abnormal. 
 
Coronary artery calcification by computed tomography 
Coronary artery calcification (CAC) was detected with a 16-slice CT scanner (Philips 
Brilliance, Philips Healthcare, Andover) using non-contrast prospective 
electrocardiography-gated acquisition. Estimated absorbed radiation was 0.6-1.2 mSv. 
CAC score (CACS) was calculated by the Agatston method and graded as 1-99, 100-
399 and ≥40017. CACS was quantified by three trained technicians blinded to other 
imaging results and supervised by experienced physicians. 
 
Definition of subclinical atherosclerosis  
Subclinical atherosclerosis was defined as the presence of atherosclerotic plaques in the 
carotid, aortic or ilio-femoral territories or CACS≥1. The multi-territorial extent of 
subclinical atherosclerosis was defined according to the number of vascular sites 
affected (right carotid, left carotid, abdominal aorta, right ilio-femoral, left ilio-femoral 
and coronary arteries). Participants were classified as disease-free (0 vascular sites 
affected) or having focal (1 site), intermediate (2-3 sites) or generalized atherosclerosis 
(4-6 sites).  
 
Statistical analysis  
Baseline characteristics were calculated using mean and standard deviation for 
continuous variables and count and proportions for categorical variables. Age and 





were examined using logistic regression models. The reproducibility of ultrasound 
measurements was studied by replicating the analysis of a random sample of 60 studies 
3 months after the initial assessment. Cohen’s Kappa and intraclass correlation 
coefficients were used to quantity agreement between measurements. Statistical 
analyses were conducted using Stata 12 (StataCorp, College Station, TX, USA).  
 
RESULTS 
The PESA cohort comprised 4184 participants (78% of the eligible population). At the 
time of publication, 34 individuals (0.8%) had discontinued the study and 84 (2.0%) 
were either excluded for missing data or were pending evaluation, resulting in 4066 
participants eligible for analysis. After excluding non-interpretable images (64 
participants, 1.5%), the population available for imaging analysis was 4002 (98% of the 
cohort). Only 1 case of abnormal ABI was detected in the first 2536 participants, and 
therefore the protocol was amended to discontinue measurement of ABI in subsequent 
examinations. Baseline demographic characteristics and traditional risk factors are 
summarized in Table 1. The average age of participants was 45.8 years, 63.3% were 
male and 99.9% Caucasian. The most prevalent risk factor was dyslipidemia (41.6%), 
followed by smoking (20.5%), family history (15.9%), hypertension (11.8%), and 
diabetes (2.0%). Overall, the presence of risk factors was higher in men, with the 
exception of smoking (23.4% women and 18.9% men) and family history (16.6% 
women and 15.5% men). Most participants (62.1%) had at least one risk factor, 18.4% 
had two and 5.2% had three or more. Aside from family history, the prevalence of risk 
factors increased with age except for smoking and diabetes in women (Table S1). There 
were no significant differences on the distribution of the group not included in the 






Prevalence, vascular distribution and extent of subclinical atherosclerosis  
Overall prevalence of subclinical atherosclerosis (presence of plaque or CACS≥1) was 
62.5%. Plaques were detected by ultrasound in 60.2% of participants (31.3% in the 
carotids, 24.5% in the aorta and 43.7% in the ilio-femoral arteries) and 17.7% had CAC 
(CACS 1-99 in 14.4%, 100-399 in 2.6% and ≥400 in 0.7%). Of those with CACS≥1, 
87.4% had plaques present at other vascular sites, whereas 54.4% of participants with 
CACS=0 had plaques in other territories. Classification of participants according to the 
extent of atherosclerosis showed that disease was focal in 21.2%, intermediate in 27.8% 
and generalized in 13.4%.  
 
Subclinical atherosclerosis was more prevalent in men (70.7% vs. 48.4% in women) 
across all vascular territories, with differences most pronounced in the ilio-femoral and 
coronary arteries (Figure 1). Of the 23 participants with CACS≥400, only one was 
female (Table S1). Atherosclerosis prevalence increased with age for both genders and 
across all vascular territories, and only the presence of aortic disease was found to be 
independent of gender (Figure 2). The prevalence of atherosclerosis affecting multiple 
vascular sites was greater in men, increased with age, and was related to the presence of 
CV risk factors (Figure S1, Table S2). Notably, the extent of subclinical atherosclerosis 
in men aged 40-44 years, was similar to that in women 5 to 10 years older (Figure S1).  
 
Associations between risk factors and subclinical atherosclerosis in different territories 
are shown in Table 2. Age and male gender were significantly associated with the 
presence of plaque in any territory, and particularly with CAC. All risk factors were 





significance for the association of diabetes or hypertension with aortic disease and of 
family history with carotid disease. Diabetes was most strongly associated with carotid 
disease and CAC, whereas smoking had a stronger association with aortic and ilio-
femoral disease and family history had a stronger association with CAC. The presence 
of ilio-femoral disease was more strongly correlated with aortic disease and CAC than 
with carotid disease. Furthermore, having disease in the ilio-femorals corresponds to a 
69.7% probability of finding disease in any other territory explored. Conversely, the 
absence of plaque in the ilio-femorals confers a 66.7% probability of being disease-free 
in the other vascular territories. In participants with carotid disease, the odds ratio for 
co-existing plaque was slightly higher in the aortic and ilio-femoral territories compared 
with CAC, and the probability of subclinical atherosclerosis in any other territory was 
71.7%, with a negative predictive value of 54.6%.  
 
Intima-media thickness and subclinical atherosclerosis 
Mean IMT was 0.59 mm in carotid arteries and 0.61 mm in femoral arteries. Abnormal 
IMT (>0.9 mm)14 was detected in 8.7% of participants, and was more frequent in 
femoral than in carotid arteries (8.4% vs. 0.8%). Prevalence of abnormal IMT was 
higher in men and increased with age (Table S1). The sensitivity, specificity, and 
positive and negative predictive values for IMT to detect subclinical atherosclerosis 
were 13.8%, 99.8%, 99.1% and 41.0%, respectively.  
 
CV risk scales and subclinical atherosclerosis 
The FHS 10-year score was 5.9%, and most participants (85.0%) were at low-risk, 
compared with 13.6% at moderate risk and 1.4% at high risk. Similarly, most 





moderate and 0.07% at high risk. To assess longer-term risk, mean FHS 30-year score 
was calculated, yielding a mean value of 17.8% and higher proportions of participants at 
moderate and high-risk (30.3% and 35.0%, respectively).  
 
The relationship between risk categories according to CV risk scales and subclinical 
atherosclerosis is shown in Figures 3 and 4. Among participants at low 10-year FHS 
risk, 58.2% had subclinical atherosclerosis, including 35.7% with intermediate or 
generalized disease. Most FHS high-risk participants (94.6%) had atherosclerosis, with 
intermediate or generalized disease in 85.5%. Similarly, among participants with a low 
European SCORE, 57.5% had subclinical atherosclerosis, including 34.7% with 
intermediate or generalized disease, and all high-risk participants had intermediate or 
generalized disease. Given the low numbers of individuals at high-risk using the 10-year 
FHS scale (55 participants) or the European SCORE (3 participants), we also examined 
the relationship between atherosclerosis and 30-year FHS score. Among individuals at 
high 30-year FHS risk, 82.5% had subclinical atherosclerosis, with intermediate or 
generalized disease in 65.8%, whereas of low-risk individuals, 43.1% had 
atherosclerosis and 21.8% had intermediate or generalized disease. Such associations 
were also observed for each vascular territory analyzed separately (Figures S3, S4 and 
S5).  
 
Participants classified at low-risk but who had ≥2 vascular sites affected were further 
analyzed to investigate the involvement of specific arterial sites. In individuals with 
intermediate or generalized atherosclerosis and a low 10-year FHS risk (n= 1215), 
prevalence of ilio-femoral disease was 38.4%, carotid disease 28% and aortic disease 





low-risk individuals with intermediate or generalized disease (n= 1174) was 43.4% for 
ilio-femoral arteries, 31.0% for carotids, 24.3% for aorta and 17.4% for CACS≥1.  
 
In light of recent US guidelines for statin therapy18, a further analysis was performed 
using the 10-year ASCVD risk algorithm, an atherosclerotic CV risk calculator based on 
Pooled Cohort Equations6, 18, to compare individuals at ≥7.5% and <7.5% risk. The 
≥7.5% 10-year ASCVD risk population (9.9%) had a significantly higher prevalence of 
subclinical atherosclerosis (91.5% vs 59.6%, p<0.001) and of intermediate and 
generalized disease (35.8% and 27.1% vs 42.5% and 10.3%; p<0.001). Comparison by 
vascular territory revealed carotid disease in 57.0% vs 28.6%, aortic disease in 42.3% vs 
22.7%, CACS≥1 in 45.1% vs 14.8%, and ilio-femoral disease in 79.4% vs 40.1% for the 
≥7.5% vs <7.5% risk groups, respectively (p<0.001 for all comparisons). 
 
DISCUSSION 
The main findings from the PESA cohort are as follows: 1) Subclinical atherosclerosis 
is highly prevalent in this middle-aged asymptomatic population; 2) The ilio-femoral 
territory is the most frequently affected vascular site in the early stages of 
atherosclerosis; 3) Most individuals classified at high-risk by traditional risk scales 
(FHS and European SCORE), had subclinical atherosclerosis, but atherosclerosis is also 
present in nearly 60% of participants classified at low risk, with intermediate or 
generalized disease in one-third. Ongoing long-term PESA follow-up over at least 6 
years will enable the study of associations between subclinical disease evaluated at 
baseline and subsequent occurrence of CV events. 
 





Few population studies have investigated the prevalence and extent of subclinical 
atherosclerosis across multiple vascular sites in a middle-aged population, despite the 
fact that atherosclerosis is a systemic disease with a long latent subclinical phase. In the 
MESA and CARDIA studies, evaluation of atherosclerosis was limited to carotid IMT 
and CAC3, 5. The ARIC study focused only on carotid and popliteal territories assessed 
by ultrasound19. The Heinz Nixdorf Recall, High Risk Plaque, and Rotterdam studies 
recruited older populations with prior CV disease or a high-risk profile1, 20, 21. Using an 
innovative multi-territory evaluation, the PESA study detects a high prevalence of 
subclinical disease, with almost 50% of participants classified as having intermediate or 
generalized disease despite being predominantly at low-risk according to traditional risk 
scoring systems. This finding is probably due to the examination of several territories, 
including vascular areas more susceptible to disease such as the ilio-femoral arteries, 
which were not explored in earlier studies. Other studies that did investigate multiple 
vascular sites included only men with at least one risk factor22, examined participants at 
higher risk23, utilized basic imaging techniques (for example, aortic calcification by 
CT), or explored fewer territories24.  
 
The added value of a multi-territory vascular evaluation of CV risk is supported by a 
study of 10,000 participants, showing that scanning only carotids or only femorals 
predicts on average 15% and 13% fewer events than examining both territories25. This 
finding supports the view that the wider sampling that comes from exploring several 
territories overcomes the problem of not detecting a lesion when examining only one 
territory. The predictive value of multi-territory imaging will be assessed in detail with 
the appearance of events during PESA follow-up. The prognostic relevance of 





shown strong associations between CV events and presence of subclinical carotid and 
coronary disease4. Also, the Northern Manhattan Study demonstrated that subclinical 
carotid plaque is a precursor of CV events26. In the CAFES-CAVE study, the evaluation 
of subclinical disease in the carotids and also in the femoral arteries was associated with 
CV events in a 10-year follow-up25. These studies highlight the potential value of 
evaluating subclinical atherosclerosis in multiple territories for CV event prediction.  
 
The association of increased prevalence of subclinical atherosclerosis with male gender 
and increased age is consistent with previous reports27, and may be related to the natural 
history of the disease. Interestingly, the risk of atherosclerosis in men is similar to that 
in women aged five to ten years older in this cohort. This discovery may assist in 
determining the most appropriate time window for atherosclerosis screening and 
intensification of primary CV prevention. We also found that individuals at ≥7.5% 10-
year ASCVD risk had substantial atherosclerosis compared with lower-risk individuals, 
especially regarding CAC, and had a 4-fold higher prevalence of generalized disease. 
This interesting finding is in line with the proposed intensification of statin treatment in 
the most recent guidelines on the treatment of blood cholesterol6. 
 
Consistent with previous studies28-30, IMT measurements did not correlate with the 
presence of subclinical atherosclerosis (presence of plaque or CACS≥1). Prevalence of 
abnormal IMT was low (8.7%), especially in the carotid arteries (0.8%), despite the 
overall high prevalence of subclinical disease (62.5%). The increasing rates of abnormal 
IMT with age suggest a confounding influence of factors not directly related to 
atherosclerosis. In addition, almost all participants with abnormal IMT also had disease 





directly determining the presence of plaques. Further evidence of the limited utility of 
IMT for assessing subclinical atherosclerosis is provided by its low sensitivity in our 
population (13.8%), the lack of standard cut-off values for normal age reference 
intervals31, and its reported poor predictive value for CV disease compared with plaque-
based markers29. In this regard, the most recent American College of 
Cardiology/American Heart Association (ACC/AHA) Guide on the assessment of CV 
risk no longer recommends carotid IMT for routine clinical assessment of the risk of a 
first atherosclerotic CV event6. 
 
The ilio-femoral territory is the most frequently affected vascular site 
The clear predominance of disease in the ilio-femoral arteries is possibly related to 
specific patterns of shear stress and disturbed flow caused by the vessel curvature32. 
Early detection of ilio-femoral disease is important since advanced stages of peripheral 
artery disease are associated with a 4-fold higher risk of myocardial infarction and a 2-
to 3-fold greater risk of stroke33, 34. The ilio-femoral territory has not been examined as 
extensively as the carotids and CAC; however, compared with carotid disease, 
peripheral artery disease has been shown to have comparable predictive power for CV 
events25. Moreover, compared with coronary artery disease, peripheral disease carries a 
greater risk of all-cause of mortality, CV death, stroke, myocardial infarction and 
hospitalization for atherotrombotic events (21.1% vs 15.2%)35. This high 
morbimortality translates into a high economic burden, with costs for treatment and 1-
year follow-up of peripheral artery disease ~5% more than for coronary artery disease36.  
 
In PESA participants, the presence of ilio-femoral disease increases the risk of 





femoral disease is strongly associated with the absence of atherosclerosis at other 
vascular sites. Thus, imaging of peripheral arteries may be a useful population-wide 
screening tool for detecting atherosclerosis in its early stages. Indeed, evaluation of the 
ilio-femoral arteries appears to be more valuable than CAC for detecting subclinical 
atherosclerosis, given the high prevalence (82.3%) of a zero CACS in this low-risk 
middle-aged population. It is also interesting that most participants with CAC also had 
plaques at other vascular sites, while half of participants without CAC were not disease-
free, indicating that CAC represents a more advanced stage of disease. ABI 
measurement for early stages of atherosclerosis is likely to be of limited value given the 
low prevalence of abnormal ABI in this young population (40-54 years), contrasting 
with the association detected between ABI and subclinical disease in older 
participants37. 
 
Subclinical atherosclerosis and traditional CV risk scales 
Current risk stratification strategies have successfully identified individuals at risk of 
CV events. Traditional risk scales include the widely used FHS and SCORE, an 
adaptation of FHS that avoids risk overestimation in European populations with less 
coronary heart disease11, 38. However, the impact of these scales in younger, low-risk 
populations is limited, with many individuals still suffering CV events and little success 
in promoting lifestyle changes39. In a cohort of 122,458 patients with coronary disease, 
9%-13% of those aged <55 years had no conventional risk factors40, indicating disparity 
between traditional risk factors and the presence of disease in younger populations.  
 
Although the FHS and the European SCORE scales were designed to assess risk of CV 





we aimed to complement these predictive models by comparing the presence and extent 
of subclinical disease across different risk categories. Interestingly, most individuals 
classified at high-risk by both algorithms have subclinical atherosclerosis, with a high 
proportion having intermediate or generalized disease. Moreover, subclinical 
atherosclerosis is present in nearly 60% of PESA participants at low risk, with one third 
having at least two sites affected. In this regard, a sub-study of the MESA and CARDIA 
population detected higher carotid IMT and higher CAC in individuals with low 10-year 
but high lifetime risk compared with individuals with low 10-year and low lifetime 
risk3. Together these results strongly suggest an association of atherosclerosis with 
characteristics different from the classic CV risk factors not considered in standard risk 
scales that will be the basis for extensive further investigation in PESA (exercise, 
sleeping disorders, etc.). Multi-territory vascular imaging appears to have the potential 
to help identify new factors and thus complement traditional risk scales, helping to 
achieve the goal of individualized risk assessment. 
 
Limitations 
This study presents a cross-sectional analysis of the PESA cohort at baseline, and 
therefore cannot yet evaluate clinical events, precluding the possibility of establishing 
causality; these current findings will be complemented by long-term follow up 
monitoring of atherosclerosis progression. The PESA population consists of middle-
aged, predominantly male white-collar workers, which may limit the generalizability of 
the results. Detection of plaques in the iliac arteries may be limited by the penetration of 
the vascular probe used and the presence of air (22.9% of iliac studies were suboptimal, 
compared with 2.3% for carotids, 10.2% for aorta, and 5.8% for femorals). However, a 





and only 1.2% of iliac studies were non-interpretable. When classifying the extent of 
subclinical atherosclerosis, aortic and coronary sites were each considered as single 
territories, and greater weight was therefore given to carotid and ilio-femoral territories; 
however, the multi-territorial extent of disease includes the concept of laterality and 
introduces a novel evaluation of atherosclerosis. Although CAC scan is a well-
established test for the evaluation of subclinical coronary disease, it is not suitable for 
non-calcified plaques. In the interest of clarity and ease of clinical application, 
atherosclerotic plaques and CAC were considered as dichotomized variables (presence 
or absence) to evaluate the extent of subclinical atherosclerosis. 
 
In conclusion, subclinical atherosclerosis is highly prevalent in a middle-aged 
asymptomatic population, with almost half the participants presenting with intermediate 
or generalized disease. Prevalence is higher in men and in the ilio-femoral arteries, 
highlighting the value of screening this territory for early detection of atherosclerosis. 
As a substantial proportion of low-risk participants had subclinical atherosclerosis, 
imaging of early atherosclerosis may be particularly valuable in this setting. Long-term 
follow up will determine whether early detection of subclinical atherosclerosis has any 
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Figure 1. Prevalence of subclinical atherosclerosis by vascular territories in PESA. 
 
Figure 2. Prevalence of subclinical atherosclerosis by age and gender in each vascular 
territory. 
 
Figure 3. Distribution of subclinical atherosclerosis detected by noninvasive imaging 
according to Framingham Heart Study risk categories. Vascular sites examined were the 
right and left carotids, abdominal aorta and the right and left ilio-femoral arteries 
(presence of plaque), and the coronary vessels (CAC). FHS scores were classified as 
low (<10%), moderate (≥10 to 20%) or high risk (>20%)10, 12. 
 
Figure 4. Distribution of subclinical atherosclerosis detected by noninvasive imaging 
according to European SCORE categories. European SCORE was classified as low 

























Age (years) 45.8±4.3 46.3±4.4 45±3.9 <0.001 
BMI (kg/m2) 26.2±3.8 27.4±3.4 24.1±3.6 <0.001 
SBP (mmHg) 116±12.5 121±11.1 109±11 <0.001 
DBP (mmHg) 72.5±9.4 74.7±9.1 68.7±8.7 <0.001 
Total cholesterol (mg/dL) 201±33.3 203±34.2 196±31.2 <0.001 
LDLc (mg/dL) 132±29.8 136±30.3 125±27.5 <0.001 
HDLc (mg/dL) 49±12.2 44.8±10.2 56.3±11.9 <0.001 
Triglycerides (mg/dL) 95±57.2 109±64 70.6±29.9 <0.001 
Fasting glucose (mg/dL) 90.6±13.8 93.4±15 85.7±9.7 <0.001 
HbA1c (%) 5.44±0.5 5.49±0.5 5.36±0.4 <0.001 
Lipid-lowering therapy 287(7.1) 242(9.4) 45(3) <0.001 
Antihypertensive therapy 309(7.6) 266(10.3) 43(2.9) <0.001 
Antidiabetic therapy 64(1.6) 56(2.2) 8(0.5) <0.001 
CV risk factors 
Dyslipidemia 1691(41.6) 1374(53.4) 317(21.2) <0.001 
Total cholesterol≥240 mg/dL 475(11.7) 345(13.4) 130(8.7) <0.001 
LDLc≥160 mg/dL 688(16.9) 522(20.3) 166(11.1) <0.001 
HDLc<40mg/dL 983(24.2) 880(34.2) 103(6.9) <0.001 
Current smoking 835(20.5) 486(18.9) 349(23.4) <0.001 
Hypertension 481(11.8) 409(15.9) 72(4.8) <0.001 
Diabetes 81(2.0) 72(2.8) 9(0.6) <0.001 
Family history of CV disease 646(15.9) 398(15.5) 248(16.6) 0.337 
Number of CV risk factors     
0 1535(37.7) 777(30.2) 758(50.8) <0.001 
1 1572(38.7) 1053(40.9) 519(34.8) <0.001 
2 746(18.4) 569(22.1) 177(11.8) <0.001 





Data are expressed as mean ± SD or n (%). BMI: Body mass index. CV: 
Cardiovascular; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LDLc: 


























Table 2. Association between the presence of atherosclerosis in individual vascular 
territories and age, gender, risk factors and vascular distribution of disease 
 
Carotid disease Coronary calcification Aortic disease Ilio-femoral disease 
Age and gender 
40-44 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
45-49 years 
1.45(1.23-1.70) 1.88(1.52-2.33) 1.72(1.44-2.06) 2.06(1.78-2.39) 
<0.001 <0.001 <0.001 <0.001 
50-54 years 
2.54(2.15-3.01) 5.09(4.13-6.28) 3.20(2.67-3.84) 4.22(3.56-5.00) 
<0.001 <0.001 <0.001 <0.001 
Female 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Male 
1.83(1.58-2.11) 7.04(5.43-9.13) 1.25(1.08-1.46) 2.76(2.41-3.17) 
<0.001 <0.001 0.004 <0.001 
Cardiovascular risk factors 
Hypertension 
1.36(1.11-1.68) 1.42(1.13-1.80) 1.10(0.88-1.37) 1.33(1.07-1.64) 
0.003 0.003 0.422 0.009 
Diabetes 
1.89(1.17-3.04) 2.18(1.33-3.60) 1.39(0.86-2.27) 2.55(1.44-4.52) 
0.009 0.002 0.183 0.001 
Smoking 
1.75(1.48-2.06) 1.57(1.27-1.93) 2.30(1.94-2.72) 2.57(2.17-3.05) 
<0.001 <0.001 <0.001 <0.001 
Dyslipidemia 
1.43(1.23-1.65) 1.65(1.38-1.98) 1.39(1.19-1.63) 1.70(1.48-1.96) 











Carotid disease (-) 
2.06(1.73-2.47) 2.80(2.40-3.27) 2.13(1.84-2.46) 












Data are expressed as odds ratio (95% confidence interval) and p value and is adjusted 
























<0.001 <0.001 <0.001 
Ilio-femoral 
disease 
2.13(1.84-2.46) 3.16(2.60-3.84) 4.85(4.09-5.75) 
(-) 





























































































CV risk factors 
Dyslipidemia 483 (48.3) 449 (54.6) 406 (57.8) 113 (15.1) 121 (23.9) 81 (36) 
Smoking 170 (17) 159 (19.3) 146 (20.8) 163 (21.8) 131 (25.9) 50 (22.2)NS 
Hypertension 84 (8.4) 124 (15.1) 179 (25.5) 13 (1.74) 34 (6.72) 25 (11.1) 
Diabetes 12 (1.2) 18 (2.19) 37 (5.27) 3 (0.4) 2 (0.4) 2 (0.89)NS 
Family history 148 (14.8) 136 (16.5) 104 (14.8) NS 123 (16.5) 91 (18.0) 32 (14.2) NS 
Number of risk factors 
0 365 (36.5) 234 (28.5) 173 (24.6) 419 (56.1) 238 (47.1) 96 (42.7) 
1 415 (41.5) 353 (42.9) 267 (38.1)NS 249 (33.3) 180 (35.6) 81 (36.0) NS 
2 181 (18.1) 181 (22.0) 193 (27.5) 71 (9.5) 67 (13.2) 38 (16.9) 
>2 39 (3.9) 54 (6.6) 69 (9.8) 8 (1.1) 21 (4.1) 10 (4.4) 
CV risk scales (%) 
10y SCORE 0.39 ± 0.23 0.77 ± 0.37 1.43 ± 0.73 0.06 ± 0.05 0.17 ± 0.09 0.42 ± 0.25 
10y FHS 5.84 ± 0.10 7.78 ± 0.13 10.3 ± 0.19 1.81 ± 0.04 3.3 ± 0.09 4.9 ± 0.18 




6.73 ± 0.98 18.6 ± 3.53 45.4 ± 5.72 0.36 ± 0.01 1.52 ± 0.48 4.37 ± 2.06 
CACS 0 854 (85.4) 629 (76.5) 401 (57.1) 727 (97.3) 480 (94.9) 203 (90.2) 
CACS 1-99 126 (12.6) 159 (19.3) 227 (32.3) 20 (2.7) 24 (4.7) 20 (8.9) 
CACS 100-399  19 (1.9) 26 (3.2) 57 (8.1) 0 (0) 2 (0.4) 1 (0.4) 
CACS ≥400  1 (0.1) 8 (1) 17 (2.4) 0 (0) 0 (0) 1 (0.4) 
IMT (mm) 
Carotid IMT  0.59 ± 0.003 0.61 ± 0.003 0.64± 0.004 0.53 ± 0.002 0.56 ± 0.003 0.60 ± 0.006 
Femoral IMT  0.60 ± 0.007 0.66 ± 0.009 0.73± 0.012 0.50 ± 0.004 0.55 ± 0.007 0.57 ± 0.011 
Carotid IMT > 0.9 7 (0.7) 4 (0.5) 18 (2.6) 0 (0) 0 (0) 2 (0.9) 






Data are expressed as mean ± SEM or n (%). CACS: Coronary artery calcium score. 
CV: Cardiovascular. FHS: Framingham Heart Study. IMT: Intima-media thickness. NS: 
Non-significant (p value >0.05). Supplemental Tables are calculated from a complete 


























Table S2. Relation between age, male gender and traditional risk factors and the extent 














Age 44.2 ± 3.77 45.4 ± 4.1 46.7 ± 4.13 48.8 ± 3.99   <0.001 
Male gender 739 (49.2) 530 (62.4) 809 (72.7) 446 (82.9) <0.001 
Smoking 199 (13.2) 154 (18.1) 271 (24.3) 195 (36.2) <0.001 
Diabetes 8 (0.5) 14 (1.7) 18 (1.6) 34 (6.3) <0.001 
Dyslipidemia 442 (29.4) 318 (37.5) 548 (49.2) 345 (64.1) <0.001 
Hypertension 99 (6.6) 82 (9.7) 158 (14.2) 120 (22.3) <0.001 
Family history 221 (14.7) 121 (14.3) 182 (16.4) 110 (20.4) <0.001 
 










































Figure S2. Association of subclinical atherosclerosis with the 10-year Framingham 
















Figure S3. Association of subclinical atherosclerosis with the 30-year Framingham 
























Figure S4. Association of subclinical atherosclerosis with European SCORE risk 
according to vascular territory 
 
 
